Gastroenterology News

BOSTON — Chronic diarrhea is an “incredibly common” condition, with about one out of 20 patients presenting with symptoms, according to Brian E. Lacy, MD, PhD, FACG, a professor of medicine at the Mayo Clinic.

In this Healio video exclusive, Jeffrey Roberts, MS, BSc, shares details about World IBS Day, April 19, which aims to raise awareness and support for patients with irritable bowel syndrome with the theme, “Light Up the Sky for IBS.”

In this video, Laurie Keefer, PhD, Healio’s 2023 Allied Health Provider of the Year, underscores the importance of providing interventions to patients at the time of a GI diagnosis — not just when symptoms of depression or anxiety develop.

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

Most patients with all-cause and norovirus-associated acute gastroenteritis have only one health care encounter, primarily in the outpatient setting, researchers found in a study.

Glucagon-like peptide-1 receptor agonists were linked to a significantly higher risk for aspiration pneumonia after gastrointestinal endoscopy, particularly among those undergoing upper endoscopy and propofol sedation, according to a study.

The initiation of medications for alcohol use disorder, or AUD, at discharge reduced the incidence of several outcomes like hospital readmissions and ED visits, a study showed.

A quality performance measure that tracks follow-up colonoscopy rates within 6 months of an abnormal stool-based screening test was feasible and had a median reliability of 94.5% across health care organizations, according to researchers.

During Irritable Bowel Syndrome Awareness Month, an advocacy group launched the #IBSDilemma campaign to focus on the unique challenges that individuals living with this common gastrointestinal disorder may encounter in daily life.

A 75-year-old man presents for evaluation of profound fatigue of at least 3 months’ duration.